CymaBay Therapeutics Inc. (CBAY) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.30 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -9.38%. A quarter ago, it was expected that this company would post a loss of $0.30 per share when it actually produced a loss of $0.32, delivering a surprise of -6.67%.Over the last four quarters, the company ha ...

Gilead Sciences, Inc. has proposed to acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion.  U.S. FDA accepted seladelpar NDA for priority review, and seladelpar marketing applications were submitted to the EMA and MHRA for review in Europe and the U.K. Due to the pending transaction with Gilead, CymaBay will not be hosting a conference call to review the financial results for the fourth quarter ended December 31, 2023 or commenting on its financial guidance for the future q ...

Net cash provided by financing activities was $345.8 million for the year ended December 31, 2023 compared to $24.6 million in the prior year. During the year ended December 31, 2023, we received net proceeds of approximately $242.8 million from the September 2023 public offering and approximately $92.4 million from the January 2023 public offering. In addition, proceeds of $10.6 million were received from the issuance of common stock pursuant to our equity award plans during the year ended December 31, 202 ...

-  Seladelpar demonstrated normalization of liver biomarkers and significant reductions across three measures of patient-reported itch vs. placebo -  NEWARK, Calif., Feb. 21, 2024 /PRNewswire/ -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that The New England Journal of Medicine (NEJM) has published detailed results from the RESPONSE Phase 3 trial evaluating seladelpar, an investi ...

Key TakeawaysGilead Sciences is buying CymaBay Therapeutics, giving Gilead access to CymaBay's lead treatment for liver disease.Gilead will pay $4.3 billion or $32.50 per share in cash for CymaBay, a 26.5% premium over CymaBay's closing price Friday.CymaBay shares skyrocketed Monday to an all-time high after the news.Shares of CymaBay Therapeutics (CBAY) soared to an all-time high Monday after Gilead Sciences (GILD) announced it's buying the developer of medicine for liver and other chronic diseases for $4. ...

CymaBay (NASDAQ:CBAY) stock is rising higher on Monday after the clinical-stage biopharmaceutical company announced an acquisition agreement with Gilead Sciences (NASDAQ:GILD).That deal has Gilead Sciences agreeing to acquire CymaBay for $4.3 billion. This has it agreeing to pay $32.50 per share in cash for CBAY stock via a tender offer. That’s a 27% premium compared to the stock’s closing price on Friday.Gilead Sciences is acquiring CymaBay for its lead product candidate, seladelpar. This is a treatment in ...

CymaBay Therapeutics Inc (NASDAQ: CBAY) opened more than 25% up this morning after Gilead Sciences Inc (NASDAQ: GILD) said it will buy the biopharmaceutical company for $4.3 billion.Details of Gilead-CymaBay agreementCopy link to sectionThe said deal values CymaBay at $32.50 per share. Lead asset of this Newark-headquartered firm is “seladelpar” – a candidate drug for primary biliary cholangitis. The acquisition, therefore, will help Gilead Sciences expand its liver portfolio.The news arrives only days afte ...

-  FDA has granted Priority Review with a target PDUFA date of August 14 - NEWARK, Calif., Feb. 12, 2024 /PRNewswire/ -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) for seladelpar, an investigational treatment for the management of primary biliary cholangitis (PBC) including pruritus in adults w ...

Gilead Sciences Inc. GILD, -0.18% said Monday it has reached a deal to acquire CymaBay Therapeutics Inc. CBAY, +2.92% for $32.50 per share in cash, a 27% premium to CymaBay’s closing price Friday, for a total deal equity value of $4.3 billion. CymaBay’s lead asset is seladelpar, an investigational treatment for primary biliary cholangitis, a type of liver disease that causes bile-duct damage. The U.S. Food and Drug Administration has granted priority review to seladelpar, and a regulatory decision is expec ...

FOSTER CITY, Calif. & NEWARK, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and CymaBay Therapeutics, Inc. (Nasdaq: CBAY) announced today a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion. The addition of CymaBay’s investigational lead product candidate, seladelpar for the treatment of primary biliary cholangitis (PBC) including pruritus, complements Gilead’s existing liver portfolio and aligns with its long-st ...